ReviewDeutsches Arzteblatt international2026
The Endovascular Treatment of Aortic Arch Pathologies.
Review in Deutsches Arzteblatt international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe endovascular treatment of pathologies of the aortic arch has become established in recent years, not only as a complementary treatment option but also as an alternative to open surgery for selected patients. The prevalence of thoracic aortic aneurysms is approximately 0.16%.
methodsIn this narrative review, we present the endovascular treatment options for aortic arch disorders.
resultsThe endovascular treatment of aortic arch pathologies has been evaluated to date mainly in uncontrolled, retrospective studies. A prerequisite for endovascular treatment of the aorta is the availability of an adequate landing zone in which the stent graft can be anchored both proximally and distally. Stable, asymptomatic aneurysms can be treated conservatively with frequent follow-up. Endovascular aortic arch procedures have high technical success rates (branched thoracic endovascular aortic repair: 96.3%, fenestrated thoracic endovascular aortic repair: 95.7%), a 30-day mortality of 6.3%, and a 30-day stroke rate of 9.4% (weighted average values). The endoleak rates range from 2.6% to 37.6% (weighted average, 19.6%). Especially for patients with a high surgical risk, this minimally invasive method can be used as an alternative to open surgery in specialized centers. Indications must be determined on a case-by-case basis.
conclusionThe published studies vary widely in case numbers and patient collectives; randomized controlled trials are lacking, as is a direct comparison with open aortic arch replacement surgery. Improvements in aortic arch prostheses enable improved, more individualized treatment; the risk profile of each patient must be considered by the interdisciplinary aorta team along with the advantages and disadvantages of the various available types of prosthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.